Assessment of disease progression in dysferlinopathy
A 1-year cohort study

Ursula Moore, MBBchir, Marni Jacobs, PhD, Meredith K. James, PT, Anna G. Mayhew, PT, PhD, Roberto Fernandez-Torron, MD, Jia Feng, MSc, Avital Cnaan, PhD, Michelle Eagle, PT, PhD, Karen Bettinson, MSc, Laura E. Rufibach, PhD, Robert Muni Lofra, PT, Andrew M. Blamire, PhD, Pierre G. Carlier, MD, PhD, Plavi Mittal, PhD, Linda Pax Lowes, PT, PhD, Lindsay Alfano, DPT, Kristy Rose, PT, PhD, Tina Duong, MPT, Katherine M. Berry, PT, Elena Montiel-Morillo, PT, Irene Pedrosa-Hernández, PT, Scott Holsten, PT, Mohammed Sanjak, PT, PhD, Ai Ashida, DPT, Chikako Sakamoto, PT, Takayuki Tateishi, PT, Hiroyuki Yajima, PT, Aurélie Canal, PT, Gwenn Ollivier, PT, Valerie Decostre, PhD, Juan Bosco Mendez, MD, Nieves Sánchez-Aguilera Praxedes, PT, Simone Thiele, PT, Catherine Siener, PT, MHS, Jeanine Shierbecker, PT, Julaine M. Florence, PT, MHS, DPT, Bruno Vandevelde, Brittney DeWolf, PT, DPT, PCS, Meghan Hutchence, BSc, PT, Richard Gee, MPT, Juliana Prügel, PT, Elke Maron, PT, Heather Hilsden, BA, Hanns Lochmüller, MD, Ulrike Grieben, MD, Simone Spuler, MD, Carolina Tesi Rocha, MD, John W. Day, MD, Kristi J. Jones, MD, PhD, Diana X. Bharucha-Goebel, MD, Emmanuelle Salort-Campana, MD, Matthew Harms, MD, Alan Pestronk, MD, Sabine Krause, MD, PhD, Olivia Schreiber-Katz, MD, Maggie C. Walter, MD, MA, Carmen Paradas, MD, PhD, Jean-Yves Hogrel, PhD, Tanya Stojkovic, MD, Shin'ichi Takeda, MD, PhD, Madoka Mori-Yoshimura, MD, PhD, Elena Bravver, MD, Susan Sparks, MD, Jordi Díaz-Manera, MD, PhD, Luca Bello, MD, PhD, Claudio Semplicini, MD, PhD, Elena Pegoraro, MD, PhD, Jerry R. Mendell, MD, Kate Bushby, MD, and Volker Straub, MD, for the Jain COS Consortium

Correspondence
Prof. Straub
volker.straub@
newcastle.ac.uk

Abstract

Objective
To assess the ability of functional measures to detect disease progression in dysferlinopathy over 6 months and 1 year.

Methods
One hundred ninety-three patients with dysferlinopathy were recruited to the Jain Foundation's International Clinical Outcome Study for Dysferlinopathy. Baseline, 6-month, and 1-year assessments included adapted North Star Ambulatory Assessment (a-NSAA), Motor Function Measure (MFM-20), timed function tests, 6-minute walk test (6MWT), Brooke scale, Jebsen test, manual muscle testing, and hand-held dynamometry. Patients also completed the ACTIVLIM questionnaire. Change in each measure over 6 months and 1 year was calculated and compared between disease severity (ambulant [mild, moderate, or severe based on a-NSAA score] or nonambulant [unable to complete a 10-meter walk]) and clinical diagnosis.

Results
The functional a-NSAA test was the most sensitive to deterioration for ambulant patients overall. The a-NSAA score was the most sensitive test in the mild and moderate groups, while the 6MWT was most sensitive in the severe group. The 10-meter walk test was the only test showing significant change across all ambulant severity groups. In nonambulant patients, the MFM domain 3, wrist flexion strength, and pinch grip were most sensitive. Progression rates did not differ by clinical diagnosis. Power calculations determined that 46 moderately affected patients are required to determine clinical effectiveness for a hypothetical 1-year clinical trial based on the a-NSAA as a clinical endpoint.

Conclusion
Certain functional outcome measures can detect changes over 6 months and 1 year in dysferlinopathy and potentially be useful in monitoring progression in clinical trials.

ClinicalTrials.gov identifier:
NCT01676077.

From the John Walton Muscular Dystrophy Research Centre (U.M., M.K.J., A.G.M., R.F.-T., M.E., K.B., R.M.L., H.H., H.L., K.B., V.S.), Newcastle University and Newcastle Hospitals NHS Foundation Trust, MRC Centre for Neuromuscular Diseases, Institute of Genetic Medicine, Central Parkway, Newcastle Upon Tyne, UK; Center for Translational Science (M.J., J.F., A. Cnaan), Division of Biostatistics and Study Methodology, Cooperative International Neuromuscular Research Group (T.D., B.D.), and Department of Neurology (D.X.B.-G.), Children's National Health System; Pediatrics, Epidemiology and Biostatistics (M.J., A. Cnaan), George Washington University, Washington, DC; Neuromuscular Area (R.F.-T.), Biodonostia Health Research Institute, Neurology Service, Donostia University Hospital, Donostia-San Sebastian, Spain; Jain Foundation (L.E.R., P.M.), Seattle, WA; Magnetic Resonance Centre (A.M.B.), Institute of Cellular Medicine, Newcastle University, Newcastle Upon Tyne, UK; AIM & CEA NMR Laboratory (P.G.C.), Institute of Myology, Pitié-Salpêtrière University Hospital, 47-83, Paris, France; Research Institute at Nationwide Children's Hospital (L.P.L., L.A., K.M.B., J.R.M.), The Ohio State University, Columbus; Institute for Neuroscience and Muscle Research (K.R., M. Hutchence, K.J.J.), Children's Hospital at Westmead, University of Sydney, Australia; Lucile Salter Packard Children's Hospital at Stanford (T.D.), 24349, Neurology, Palo Alto, CA; Physical Medicine and Rehabilitation (E.M.-M., I.P.-H.), Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Neuroscience Institute (S.H., M.S., E.B., S. Sparks), Carolinas Neuromuscular/ALS-MDA Center, Carolinas HealthCare System, Charlotte, NC; Department of Physical Rehabilitation (A.A., C. Sakamoto, T.T., H.Y.), National Center Hospital, National Center of Neurology and Psychiatry, Tokyo, Japan; Institut de Myologie (A. Canal, G.O., V.D., J.-Y.H., T.S.), AP-HP, GH Pitié-Salpêtrière, Paris, France; Neurorehabilitation Unit (J.B.M.), Rehabilitation Hospital Universitario Virgen del Rocío Sevilla; Neurophysiotherapy Department (N.S.-A.P.), Hospital Universitario Virgen del Rocío, Seville, Spain; Friedrich-Baur-Institute (S. Thiele, S.K., O.S.-K. M.C.W.), Department of Neurology, Ludwig-Maximilians-University of Munich, Germany; Department of Neurology (C. Siener, J.S., J.M.F., M. Harms, A.P.), Washington University School of Medicine, St. Louis, MO; Centre de Reference des Maladies Neuromusculaires PACA Réunion Rhone Alpes (B.V., E.S.-C.), Hopital de la Timone, Aix-Marseille Université, France; ELAN-PHYSIO (J.P., E.M.), Praxis für Physiotherapie Maron; Charite Muscle Research Unit (U.G., S. Spuler), Experimental and Clinical Research Center, a joint cooperation of the Charité Medical Faculty and the Max Delbrück Center for Molecular Medicine, Berlin, Germany; Department of Neurology and Neurological Sciences (C.T.R., J.W.D.), Stanford University School of Medicine, CA; NIH (D.X.B.-G.), Bethesda, MD; Neuromuscular Unit (C.P.), Department of Neurology, Hospital U. Virgen del Rocío/Instituto de Biomedicina de Sevilla, Spain; Department of Neurology (S. Takeda, M.M.-Y.), National Center Hospital, National Center of Neurology and Psychiatry, Tokyo, Japan; Centro de Investigación Biomédica en Red en Enfermedades Raras (J.D.-M.); Neuromuscular Disorders Unit (J.D.-M.), Neurology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; and Department of Neuroscience (L.B., C. Semplicini, E.P.), University of Padova, Italy.

Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.

The Jain COS Consortium coinvestigators are listed in the Appendix at the end of the article.

The Article Processing Charge was funded by the Jain Foundation.

Glossary

a-NSAA = adapted North Star Ambulatory Assessment; **COS** = Jain Clinical Outcome Study in Dysferlinopathy; **HHD** = hand-held dynamometry; **LGMD2B** = limb girdle muscular dystrophy 2B; **MFM** = Motor Function Measure; **MMT** = manual muscle testing; **6MWT** = 6-minute walk test; **SRM** = standardized response mean.

Dysferlinopathy is a rare, recessively inherited muscular dystrophy caused by mutations in the *DYSF*[1-4] gene. Potential therapies are in development, and some of them have entered human clinical trials (NCT02579239, NCT01863004, NCT02710500). As the development of newly licensed and emerging treatments for Duchenne muscular dystrophy[5,6] and spinal muscular atrophy type 1[7] has shown, proving efficacy and satisfying regulators can be difficult in slowly progressive and varied conditions.[8]

Appropriate powering of a clinical trial requires understanding of disease progression and responsiveness of various outcome measures over time.[9] Selection of outcome measures for clinical trials in dysferlinopathy is particularly challenging. Dysferlinopathy is characterized by a range of ages at onset and patterns of weakness and severity,[4,10] variable rate of progression,[4] modifying factors that are not clearly elucidated,[10-13] and no appropriate measures for monitoring progression. While some measures such as the Motor Function Measure (MFM) have been shown to be reliable in dysferlinopathy,[14] the variability of progression makes it difficult to demonstrate responsiveness in small cohorts.

The Jain Clinical Outcome Study in Dysferlinopathy (COS) aims to address these difficulties by characterizing the clinical, biochemical, and radiologic parameters of 209 patients with dysferlinopathy over 3 years.

This article summarizes findings from a planned interim analysis of baseline, 6-month, and year 1 data to determine whether disease progression is detectable and which measures are most able to detect this progress. We propose a power calculation using the most sensitive measures to determine a potential clinical trial cohort required to demonstrate significant functional change.

Methods

The COS study

The COS study is an international collaborative study of patients with a genetic and/or protein assay–confirmed diagnosis of dysferlinopathy.[4] Screening, baseline, 6-month, and 1-year visits took place between October 2012 and March 2016. One hundred ninety-seven of the original 209 recruited patients completed a baseline visit. Of the original 209 patients, 7 did not meet inclusion criteria, and 5 chose not to continue past the screening visit (figure 1). Full inclusion and exclusion criteria, the study protocol, and patient demographics have been described previously.[4]

Standard protocol approvals, registrations, and patient consents

The study was initially approved by the following: NRES Committee North East—Newcastle & North Tyneside on February 2, 2012 (reference 211/NE/0360/R&D 5918). The study was also approved by ethics review boards in each country. All patients provided written informed consent. The trial was registered at ClinicalTrials.gov (NCT01676077).

Functional outcome measures

Clinical assessments were standardized through trainings at investigator meetings, and all evaluations were performed by trained clinicians. Assessments included the adapted North Star Ambulatory Assessment (a-NSAA),[4] MFM-20, timed function tests (timed rise from floor, 10-m walk/run, 4-stair climb and descend, Timed Up and Go, and the 6-minute walk test [6MWT]), Brooke Upper Extremity Scale, Jebsen Hand Function Test, manual muscle testing (MMT), and hand-held dynamometry (HHD). No assessments have been specifically validated in a dysferlin-specific population. These assessments were chosen because of their widespread suitability for limb girdle muscular dystrophy. The MFM-20 was selected over the MFM-32 to reduce patient fatigue and duplication. All assessments were attempted for ambulant patients. Non-ambulant patients did not complete the a-NSAA or ambulation-based timed function tests.

Muscle strength was assessed with an 11-point scale for MMT.[4] The best of 3 attempts for HHD was used for analysis.

Functional ability was assessed with qualitative scales and timed tests. Total scores were calculated for the a-NSAA[15] in ambulant patients, and the MFM-20 and the Brooke scale were calculated in all patients. The MFM-20 was also analyzed on the basis of its 3 components: D1 (standing and transfers), D2 (axial and proximal), and D3 (distal). Any patient with an incomplete score was excluded from analysis for that test. To account for patients who became nonambulant or unable to complete timed function tests due to disease progression, timed test values were converted to velocity measures (either meter per second or task per second), with a 0-m/s velocity assigned for the first instance a patient was unable to complete the test.

Patient perception of progression

The ACTIVLIM questionnaire, a Rasch-built patient-reported outcome measure,[16] was used to capture patient-reported functional ability. The total score, out of a maximum of 36, was compared between visits. A higher score indicates greater functional ability.

Figure 1 Flowchart of patient numbers at each visit

Number of patients who completed each assessment (baseline, 6 months, and 12 months) and how many of them were used for each analysis window.

Statistical analysis

Statistical analysis was completed with SAS 9.3 (SAS Institute Inc, Cary, NC). Mean and median change scores were calculated for each test between baseline and 6 months, 6 months and year 1, and baseline and year 1. Data from some visits were excluded if the visit occurred ±2 months outside the scheduled appointment date. A majority of functional outcome measures were not normally distributed; thus, comparisons between baseline and follow-up time points were conducted with the Wilcoxon signed rank-sum test and standardized response mean (SRM).[17] A comparison was made between the performance of patients with the most common clinical diagnoses of limb girdle muscular dystrophy 2B (LGMD2B) and Miyoshi myopathy with Kruskal-Wallis test with Steel-Dwass-Critchlow-Fligner correction for multiple comparisons.[18]

Nonambulant patients (unable to walk 10 meters with usual orthotics and walking aids) were compared to 3 categories of ambulant patients: ambulation affected severely, moderately, or mildly. Using patients' a-NSAA scores at baseline, we defined ambulant severity categories based on a clinical impression of disease severity and binomial distribution of a-NSAA scores, with cut points of 0 to 10 (severe disease severity), 11 to 40 (moderate disease severity), and 41+ (mild disease severity). The lower cut point was based on the end of the first a-NSAA peak, and the high cut point was placed at the start of the second peak, with the wide spread in between representing a plateau between peaks. Significance was defined as $p \leq 0.05$. Results are expressed as median change (range) and p value.

Power analyses to support a hypothetical future clinical trial were conducted to estimate the sample size required to detect significant statistical differences in progression over the course of 1 year with PASS 14 software. Because change scores were normally distributed, calculations used mean change scores

and SDs of the functional measure that demonstrated most change over time. For this analysis, the a-NSAA was used, which limited estimates to ambulant patients only. Sample sizes needed to evaluate a variety of expected drug effects were calculated for reference, including halting of disease progression (i.e., assuming mean progression estimates from the current sample among untreated and no progression among treated patients), reflective of potential protein-restoring genetic therapies. An α level of 0.05, 80% power, and a treated-to-untreated ratio of 1:1 were assumed. For comparison with a widely used measure in muscular dystrophy, sample sizes were also calculated on the basis of the 6MWT.

Data availability statement

Deidentified cohort level data can be requested. All protocol assessments are in the public domain apart from the a-NSAA, which can be requested from the steering group (publication in draft). The statistical plan is detailed above. All data for this natural history study will be stored for at least 5 years after the end of the study. Data can be requested by all interested stakeholders for clinical research and trial planning. Data requests are reviewed by the Jain COS Steering Committee, who can be contacted via the corresponding author.

Results

Of the initial 197 eligible enrolled patients, 3 patients withdrew after baseline, and 1 withdrew after 6 months. This is summarized in figure 1. Patients included in this analysis were between 11 and 86 years of age at baseline and were at all stages of disease progression, from asymptomatic hyper-CKemia to nonambulant.

Functional outcome measures

Functional outcome measure results are summarized in tables 1 and 2, figure 2, and table e-1 (available from Dryad, doi.org/10.5061/dryad.tp08m60). Some of the assessments, by their

Table 1 Change in scores of functional tests from baseline to 6 months, 6 months to 1 year, and baseline to 1 year for the a-NSAA, MFM, Jebsen, Brooke, patient-reported ACTIVLIM, and 6-minute walk tests

Outcome measure	Baseline median score	Change in score, baseline–6 mo			Change in score, 6 mo–1 y			Change in score, baseline–1 y			SRM
		n	Median (range)	p Value	n	Median (range)	p Value	n	Median (range)	p Value	
Total North Star score[a]	19	130	−1.00 (−19.0 to 19.0)	<0.0001[a]	119	0.00 (−14.0 to 5.00)	0.025[a]	117	−2.00 (−16.0 to 7.00)	<0.0001[b]	0.61
Total MFM score[a]	45	161	−1.00 (−17.0 to 7.00)	<0.0001[a]	148	−0.50 (−11.0 to 11.0)	0.0226[a]	149	−1.00 (−13.0 to 6.00)	<0.0001[b]	0.44
MFM D1 score[a]	10	166	0.00 (−7.00 to 4.00)	0.0007[a]	152	0.00 (−7.00 to 6.00)	0.0033[a]	151	−1.00 (−8.00 to 6.00)	<0.0001[b]	0.4
MFM D2 score[c]	23	166	0.00 (−12.0 to 5.00)	0.0004[c]	154	0.00 (−6.00 to 10.0)	0.7945	157	0.00 (−8.00 to 5.00)	0.0171[b]	0.19
MFM D3 score[b]	11	174	0.00 (−3.00 to 2.00)	0.0655	158	0.00 (−3.00 to 3.00)	0.1431	160	0.00 (−6.00 to 2.00)	0.0011[b]	0.26
Brooke Upper Extremity Scale[b]	1	181	0.00 (−2.00 to 5.00)	0.2025	164	0.00 (−5.00 to 2.00)	0.477	164	0.00 (−2.00 to 2.00)	0.0334[b]	0.18
ACTIVLIM total score[a]	26	180	0.00 (−9.00 to 8.00)	0.0042[a]	165	0.00 (−9.00 to 10.0)	0.0026[a]	164	−1.00 (−8.00 to 6.00)	<0.0001[b]	0.46
Jebsen writing time taken, s	12.7	180	0.10 (−17.3 to 14.9)	0.5794	165	0.10 (−11.3 to 30.5)	0.56	162	−0.15 (−14.4 to 28.1)	0.7109	0.11
6-min walk distance, meters/min[c]	331	124	−4.00 (−95.0 to 123)	0.2041	112	−7.00 (−110 to 51.0)	0.0003[c]	113	−13.0 (−123 to 142)	<0.0001[b]	0.37

Abbreviations: a-NSAA = adapted North Star Ambulatory Assessment; MFM = Motor Function Measure; SLM = standardized response mean.
p Values were calculated with the Wilcoxon signed-rank method. The SRM is a measure of effect size reported for change over 1 year.
[a] Consistent significant change over 6 months.
[b] Change over 1 year.
[c] Change over one 6-month period but not both 6-month periods.

Table 2 Change scores for MMT with a possible range of scores of 0 to 10 and HHM measured with a dynamometer

	Median score at baseline, median (range)	Change in score, baseline–6 mo			Change in score, 6 mo–1 year			Change in score, baseline–1 y			SRM
		n	Median (range)	p Value	n	Median (range)	p Value	n	Median (range)	p Value	
MMT shoulder flexion	7 (1–10)	184	0.00 (−3.00 to 3.00)	0.9973	169	0.00 (−3.00 to 3.00)	0.0577	166	0.00 (−4.00 to 3.00)	0.1979	0.20
MMT shoulder abduction[a]	7 (1–10)	184	0.00 (−6.00 to 5.00)	0.2465	169	0.00 (−4.00 to 4.00)	0.1172	166	0.00 (−4.00 to 3.00)	0.011[a]	0.11
HHM elbow flexion biceps, lb[b]	16.60 (1.00–65.00)	177	−0.70 (−24.5 to 10.80)	0.0012[b]	159	−0.20 (−28.7 to 16.90)	0.9424	156	−0.60 (−30.6 to 15.10)	0.0026[a]	0.23
MMT elbow flexion biceps[b]	8 (1–10)	184	0.00 (−4.00 to 4.00)	0.0322[b]	169	0.00 (−4.00 to 4.00)	0.1412	166	0.00 (−4.00 to 4.00)	0.0016[a]	0.13
HHM elbow flexion brachioradialis, lb	16.40 (0.00–56.60)	175	−0.30 (−29.1 to 17.80)	0.1451	159	−0.10 (−20.4 to 14.40)	0.5082	156	−0.45 (−32.9 to 15.20)	0.0616	0.07
MMT elbow flexion brachioradialis	8 (1–10)	184	0.00 (−5.00 to 3.00)	0.7979	169	0.00 (−4.00 to 4.00)	0.1109	166	0.00 (−5.00 to 3.00)	0.1388	0.24
MMT elbow extension[a]	8.00 (2–10)	176	0.00 (−5.00 to 4.00)	0.1263	161	0.00 (−3.00 to 5.00)	0.9587	160	0.00 (−5.00 to 4.00)	0.0472[a]	0.03
MMT wrist flexion[a]	9 (2–10)	184	0.00 (−7.00 to 5.00)	0.0647	169	0.00 (−8.00 to 6.00)	0.3377	166	0.00 (−4.00 to 3.00)	0.0024[a]	0.15
HHM wrist flexion, lb	15.80 (0.00–46.10)	176	0.00 (−18.1 to 15.10)	0.721	161	−0.20 (−22.4 to 17.30)	0.4597	158	−0.15 (−28.3 to 15.30)	0.8098	0.04
HHM wrist extension, lb	20.40 (3.10–50.30)	178	−0.15 (−16.3 to 20.30)	0.5521	163	0.00 (−25.0 to 15.40)	0.9028	160	−0.55 (−26.9 to 17.60)	0.162	0.23
MMT wrist extension	9 (3–10)	184	0.00 (−3.00 to 4.00)	0.4453	169	0.00 (−3.00 to 4.00)	0.5773	166	0.00 (−3.00 to 3.00)	0.3273	0.16
HHM grip, lb[b]	60.00 (0.00–260.0)	172	−1.00 (−173 to 103.1)	0.1287	160	−1.00 (−83.0 to 94.40)	0.0058[b]	152	−2.00 (−186 to 94.90)	0.0004[a]	0.01
HHM pinch grip, lb[b]	24.80 (0.00–97.00)	171	0.00 (−42.0 to 39.00)	0.2784	158	−1.00 (−35.0 to 22.00)	<0.0001[b]	150	−1.00 (−34.0 to 40.00)	0.0019[a]	0.20
MMT hip flexion[a]	6 (0–10)	176	0.00 (−7.00 to 4.00)	0.3953	160	0.00 (−4.00 to 7.00)	0.1663	160	0.00 (−5.00 to 4.00)	0.0093[a]	0.18
MMT hip extension	3 (0–10)	173	0.00 (−4.00 to 5.00)	0.5764	156	0.00 (−4.00 to 5.00)	0.9785	155	0.00 (−7.00 to 4.00)	0.6247	0.04
MMT hip abduction	6 (1–10)	175	0.00 (−5.00 to 7.00)	0.2452	156	0.00 (−5.00 to 5.00)	0.5303	156	0.00 (−7.00 to 7.00)	0.5382	0.26
HHM hip abduction, lb	20.50 (2.10–71.80)	161	0.10 (−37.4 to 34.30)	0.4108	148	0.10 (−33.3 to 22.70)	0.6222	149	0.10 (−36.5 to 26.10)	0.49	0.21
MMT hip adduction[b]	2 (0–10)	175	0.00 (−5.00 to 5.00)	0.0732	156	0.00 (−4.00 to 4.00)	0.0052[b]	156	0.00 (−5.00 to 5.00)	0.0009[a]	0.16
HHM hip adduction, lb[a]	11.65 (0.00–49.60)	147	−0.10 (−25.2 to 21.30)	0.5118	133	−0.40 (−22.4 to 15.30)	0.0838	138	−1.15 (−28.4 to 17.20)	0.0168a	
MMT knee flexion[b]	4 (0–10)	173	0.00 (−5.00 to 4.00)	0.0256[b]	155	0.00 (−3.00 to 4.00)	0.6457	155	0.00 (−5.00 to 3.00)	0.014[a]	0.26
HHM knee flexion, lb[b]	9.60 (0.00–65.70)	141	−0.70 (−19.0 to 15.90)	0.007[b]	127	−0.40 (−34.1 to 14.80)	0.1201	127	−1.20 (−44.5 to 20.00)	<0.0001[a]	0.20
MMT knee extension	3 (0–10)	182	0.00 (−3.00 to 4.00)	0.5574	167	0.00 (−4.00 to 5.00)	0.2943	164	0.00 (−5.00 to 5.00)	0.5064	0.12
HHM knee extension, lb[b]	11.80 (0.00–95.30)	154	−0.55 (−35.2 to 22.60)	0.0007[b]	139	−0.20 (−39.5 to 41.10)	0.3253	138	−0.80 (−37.7 to 19.70)	0.0052[a]	0.05
MMT ankle dorsiflexion[a]	4 (0–10)	180	0.00 (−7.00 to 6.00)	0.1944	165	0.00 (−6.00 to 7.00)	0.1841	164	0.00 (−5.00 to 6.00)	0.0295[a]	0.24
HHM ankle dorsiflexion, lb[b]	11.30 (0.00–55.90)	140	−0.75 (−29.5 to 22.70)	0.0018[b]	118	0.00 (−28.8 to 30.00)	0.7194	118	−0.50 (−40.5 to 25.90)	0.0537	0.23

Continued

Table 2 Change scores for MMT with a possible range of scores of 0 to 10 and HHM measured with a dynamometer *(continued)*

	Median score at baseline, median (range)	Change in score, baseline–6 mo			Change in score, 6 mo–1 year			Change in score, baseline–1 y			SRM
		n	Median (range)	p Value	n	Median (range)	p Value	n	Median (range)	p Value	
MMT ankle plantarflexion (knee straight)[a]	3 (0–10)	157	0.00 (–10.0 to 7.00)	0.273	139	0.00 (–6.00 to 8.00)	0.212	137	0.00 (–10.0 to 8.00)	0.0193[a]	0.23
HHM ankle plantar flexors (knee straight), lb	12.60 (0.00–81.00)	140	–0.40 (–34.2 to 23.70)	0.21	127	–0.50 (–28.6 to 32.90)	0.229	123	–0.70 (–33.9 to 30.20)	0.1945	0.23
MMT ankle plantarflexion (knee flexed)[a]	3 (0–10)	173	0.00 (–6.00 to 7.00)	0.2528	154	0.00 (–5.00 to 6.00)	0.242	153	0.00 (–6.00 to 5.00)	0.0174[a]	0.04
HHM ankle plantar flexors (knee flexed), lb[b]	12.20 (0.00–57.90)	144	–0.75 (–25.6 to 29.00)	0.0138[b]	127	–0.30 (–34.5 to 22.10)	0.2234	124	–1.15 (–39.6 to 22.60)	0.002[a]	0.17
MMT ankle inversion	7 (0–10)	180	0.00 (–7.00 to 6.00)	0.6828	165	0.00 (–5.00 to 4.00)	0.8154	164	0.00 (–4.00 to 5.00)	0.6789	0.16
MMT ankle eversion[b]	5 (0–10)	179	0.00 (–6.00 to 4.00)	0.8232	164	0.00 (–5.00 to 4.00)	0.0003[b]	164	0.00 (–6.00 to 3.00)	0.013[a]	0.21

Abbreviations: HHM = hand-held myometry; MMT = manual muscle testing; SRM = standardized response mean.
When the same muscle groups are tested by both methods, they are grouped together to aid interpretation. p Values were calculated with the Wilcoxon signed-rank method. No MMT or HHM assessments changed consistently over both 6-month periods. The SRM, a measure of effect size, is reported for change over 1 year. MMT and HHM assessments all showed low responsiveness to change.
[a] Change over 1 year.
[b] Change over a single 6-month period but not both 6-month periods.

nature, are suitable only for ambulant patients. In addition, some patients did not complete all assessments because of equipment or individual patient factors such as recent injury and were excluded from analysis of that assessment. The number of patients who completed each assessment is listed.

The a-NSAA, MFM-20 (total and subdomain D1), the Timed Up and Go, and timed 10-meter walk showed significant change in median score over both 6-month periods and 1 year (table 1 and figure 2); no MMT or HHD values changed consistently over both 6-month windows (table 2).

The MFM D2, some MMT and HHD, velocity to rise from floor, climb 4 stairs, descend 4 stairs, and the 6MWT showed significant change over only one 6-month window and over 1 year (tables 1 and 2 and figure 2).

The MFM D3, some MMT and HHD, and the Brooke scale showed change in median score at 1 year but did not change over either 6-month windows (tables 1 and 2).

The timed test demonstrating the greatest change in velocity was the 10-meter walk, changing −0.1 m/s (range −1.24 to 0.55 m/s) from a baseline median velocity of 1.11 m/s (range 0.00–4.55 m/s). The velocity of all timed tests at year 1 slowed by almost 10% of baseline velocity for that task (figure 2).

The Jebsen Hand Function Test and remaining MMT and HHD tests showed no change over 1 year.

The tests most responsive to change for the whole cohort, as calculated by the SRM, were NSAA (SRM 0.61), 10-meter walk/run velocity (0.56), ACTIVLIM (0.46), rise from floor velocity (0.44), and MFM total score (0.44).

When assessed by severity subgroup, for ambulant patients, the a-NSAA was the most sensitive test in the mildly (SRM 0.44) and moderately (SRM 0.89) affected groups, while the 6MWT was most sensitive in the severely affected ambulant group (SRM 0.9). The 10-meter walk was the only test showing significant change in all ambulant subgroups. For nonambulant patients, the most sensitive test was the MMT for wrist flexion (SRM 0.69), while the most sensitive combined measure was the distal domain of the MFM (SRM 0.46). Table e-1 (available from Dryad doi.org/10.5061/dryad.tp08m60) shows SRM values for all assessments by severity subgroup. Change in functional test scores (MFM and a-NSAA) did not differ between the 2 most common clinical diagnoses of LGMD2B and Miyoshi myopathy (table 3).

Patient perception of progression

Responses recorded by the ACTIVLIM questionnaire supported the deterioration in function, with the ACTIVLIM score decreasing statistically significantly over both 6 and 12 months (table 1).

Figure 2 Change in timed tests over 6 months and 1 year

A. Time to descend 4 stairs

Baseline — Year 1 (n = 104)
Baseline — 6 months (n = 112)
6 months — 1 year (n = 103)

B. Time to walk 10 meters

Baseline — Year 1 (n = 115)
Baseline — 6 months (n = 125)
6 months — 1 year (n = 115)

C. Time taken to rise from floor

Baseline — Year 1 (n = 83)
Baseline — 6 months (n = 81)
6 months — 1 year (n = 78)

D. Time to climb 4 stairs

Baseline — Year 1 (n = 105)
Baseline — 6 months (n = 112)
6 months — 1 year (n = 105)

E. Timed up-and-go

Baseline — Year 1 (n = 104)
Baseline — 6 months (n = 114)
6 months — 1 year (n = 106)

Boxplots showing range, interquartile range (IQR), and median values of time taken to perform timed tests. Paired comparisons of calculated velocity (1/time in seconds) were used to determine significant vs insignificant change in order to include those unable to complete the test. These are displayed as time taken to complete each task (rather than velocity) to aid visual interpretation. Comparisons of baseline and year 1, baseline and 6 months, and 6 months and 1 year are shown. The numbers differ depending on the number of patients completing each test at both visits. Blue shows significant change ($p < 0.05$) over 1 year; red shows if change is seen over both 6-month periods; and green shows change in only the green 6-month window. Some patients were very slow, and those taking >25 seconds to complete a test are not displayed but are included in median and IQR calculations.

Estimated sample size for trials

Estimated clinical trial sample size is highly dependent on the expected treatment effect; the smaller the effect size, the larger the sample required (table 4). For example, with the inclusion of ambulant patients of all disease severities, a total of 328 patients (164 in both the treatment and placebo groups) would be needed to detect a 50% reduction in disease progression (i.e., half the deterioration seen in the current sample) over 1 year compared to 90 patients (45 in each group) needed to detect halting in progression. The a-NSAA was chosen for its capability to detect change as demonstrated by the highest overall SRM in the current analysis. Limiting a clinical trial to a subset of patients in the moderate severity group at baseline, who showed the greatest changes in a-NSAA scores over 1 year, would reduce the total sample size to 176 for a 50% reduction in progression and 46 to detect a halt in progression. A treatment that is anticipated to improve muscle function, producing a greater effect size than simply halting progression, would require even fewer patients.

The 6MWT would require 216 ambulant patients to detect a halting of progression. However, as reflected by the high SRM in the severe-ambulant population, if trials were limited to the severe-ambulant subgroup of patients, 42 patients would be needed to detect a halting in progression with the 6MWT.

Table 3 Scores in LGMD2B and Miyoshi myopathy

Outcome	LGMD2B				Miyoshi myopathy				Kruskal-Wallis test of difference between groups
	n	Median (range)	p Value	SRM	n	Median (range)	p Value	SRM	p Value
Total North Star score	67	−2.00 (−14.0 to 5.00)	<0.0001	0.69	35	−2.00 (−16.0 to 7.00)	0.0015	0.50	0.8663
Total MFM Score	84	−1.00 (−13.0 to 6.00)	<0.0001	0.46	48	−1.00 (−10.0 to 6.00)	0.0131	0.38	0.87
MFM D1 score	85	−1.00 (−6.00 to 6.00)	0.0006	0.36	49	0.00 (−8.00 to 3.00)	0.0042	0.42	0.8898
MFM D2 score	91	0.00 (−8.00 to 4.00)	0.0201	0.25	49	0.00 (−4.00 to 5.00)	0.4588	0.08	0.8873
MFM D3 score	92	0.00 (−3.00 to 2.00)	0.0026	0.32	51	0.00 (−6.00 to 2.00)	0.2350	0.19	0.6595
MMT shoulder abduction	97	0.00 (−4.00 to 3.00)	0.0530	0.21	51	0.00 (−2.00 to 2.00)	0.2754	0.18	0.9883
MMT shoulder flexion	97	0.00 (−3.00 to 2.00)	0.2873	0.12	51	0.00 (−2.00 to 3.00)	0.8111	0.02	0.8958
MMT elbow flexion biceps	97	0.00 (−4.00 to 4.00)	0.1284	0.16	51	0.00 (−3.00 to 3.00)	0.0505	0.25	0.9713
MMT elbow flexion brachioradialis	97	0.00 (−5.00 to 3.00)	0.3926	0.11	51	0.00 (−3.00 to 3.00)	0.7598	0.03	0.9249
MMT wrist extension	97	0.00 (−3.00 to 3.00)	0.9115	0.01	51	0.00 (−2.00 to 2.00)	0.6209	0.09	0.8412
MMT wrist flexion	97	0.00 (−4.00 to 3.00)	0.0750	0.19	51	0.00 (−4.00 to 3.00)	0.0444	0.28	0.9326
MMT knee extension	96	0.00 (−3.00 to 4.00)	0.9472	0.04	51	0.00 (−3.00 to 5.00)	0.5997	0.06	0.9994
MMT ankle dorsiflexion	96	0.00 (−5.00 to 4.00)	0.0536	0.20	51	0.00 (−3.00 to 6.00)	0.1403	0.14	0.9966
MMT ankle inversion	96	0.00 (−4.00 to 4.00)	0.8853	0.01	51	0.00 (−4.00 to 5.00)	0.7866	0.04	0.9927
MMT ankle eversion	96	0.00 (−5.00 to 3.00)	0.0701	0.22	51	0.00 (−6.00 to 3.00)	0.1469	0.22	0.9941
MMT ankle plantarflexion (knee straight)[a]	78	0.00 (−5.00 to 8.00)	0.6160	0.02	44	0.00 (−10.0 to 7.00)	0.0062	0.36	0.0455
MMT ankle plantarflexion (knee flexed)	86	0.00 (−6.00 to 5.00)	0.2716	0.11	50	0.00 (−2.00 to 5.00)	0.0876	0.17	0.6968
MMT hip extension	88	0.00 (−5.00 to 4.00)	0.2450	0.12	50	0.00 (−7.00 to 2.00)	0.4626	0.37	0.423
MMT knee flexion	89	0.00 (−5.00 to 3.00)	0.3173	0.14	50	0.00 (−3.00 to 2.00)	0.0147	0.20	0.3917
MMT hip Abduction	89	0.00 (−7.00 to 7.00)	0.2638	0.12	50	0.00 (−4.00 to 6.00)	0.5599	0.10	0.4836
MMT hip Adduction	89	0.00 (−5.00 to 3.00)	0.0025	0.32	50	0.00 (−5.00 to 5.00)	0.6168	0.06	0.2017
MMT hip flexion	92	0.00 (−5.00 to 2.00)	0.1230	0.19	51	0.00 (−3.00 to 4.00)	0.1110	0.20	0.8431
MMT elbow extension	92	0.00 (−5.00 to 4.00)	0.0653	0.20	51	0.00 (−3.00 to 4.00)	0.8632	0.02	0.6868
HHM elbow flexion biceps, lb	91	−0.30 (−17.6 to 11.00)	0.0904	0.24	48	−0.85 (−23.6 to 15.10)	0.0498	0.23	0.7967
HHM elbow flexion brachioradialis, lb	91	−0.60 (−20.5 to 8.20)	0.2003	0.19	48	0.20 (−21.0 to 15.20)	0.5768	0.09	0.9248
HHM wrist extension, lb[a]	93	−1.40 (−17.4 to 14.60)	0.0173	0.21	50	1.40 (−15.5 to 17.60)	0.0798	0.15	0.0187
HHM wrist flexion, lb	93	−0.10 (−16.6 to 15.30)	0.8544	0.03	48	0.60 (−10.4 to 7.60)	0.5540	0.05	0.8952
HHM grip, lb	93	−1.00 (−186 to 87.10)	0.0085	0.27	42	−2.00 (−85.0 to 62.90)	0.1015	0.25	0.9728
HHM pinch grip, lb	93	−1.00 (−31.0 to 40.00)	0.0175	0.19	42	0.00 (−27.0 to 16.00)	0.2026	0.28	0.9623
HHM knee extension, lb	81	−0.10 (−30.3 to 15.50)	0.2259	0.17	42	−1.10 (−36.6 to 19.70)	0.0215	0.24	0.5599
HHM knee flexion, lb	73	−1.00 (−11.6 to 16.60)	0.0276	0.14	39	−1.00 (−13.5 to 20.00)	0.0011	0.21	0.6533
HHM hip abduction, lb	86	−0.10 (−14.7 to 19.20)	0.8929	0.08	48	0.90 (−36.5 to 26.10)	0.0948	0.11	0.3955

Continued

| Outcome | LGMD2B | | | | Miyoshi myopathy | | | | Kruskal-Wallis test of difference between groups |
	n	Median (range)	p Value	SRM	n	Median (range)	p Value	SRM	p Value
HHM hip adduction, lb	82	−1.00 (−20.8 to 13.40)	0.1396	0.16	41	−1.10 (−15.5 to 17.20)	0.2555	0.07	0.9905
HHM ankle dorsiflexion, lb	68	−0.65 (−18.5 to 17.00)	0.0833	0.15	35	0.00 (−22.2 to 25.90)	0.8751	0.01	0.5334
HHM ankle plantar flexors (knee flexed), lb	71	−1.00 (−23.0 to 20.90)	0.0331	0.24	37	−1.20 (−10.7 to 16.10)	0.1155	0.11	0.9482
HHM ankle plantar flexors (knee straight), lb	71	−1.00 (−27.0 to 17.30)	0.1283	0.18	36	−0.45 (−30.6 to 14.40)	0.9234	0.08	0.69
Brooke Upper Extremity Scale	97	0.00 (−1.00 to 2.00)	0.0301	0.21	51	0.00 (−1.00 to 1.00)	0.3877	0.17	0.9764
ACTIVLIM total score	95	−1.00 (−8.00 to 4.00)	<0.0001	0.51	51	−1.00 (−8.00 to 6.00)	0.0520	0.28	0.8076
Jebsen writing time taken, s	95	−0.20 (−14.4 to 28.10)	0.6479	0.15	49	0.50 (−10.5 to 6.40)	0.5693	0.04	0.9795
6-min walk test total distance, meters/min	65	−8.00 (−123 to 71.00)	0.0137	0.33	34	−15.50 (−108 to 142.0)	0.0607	0.24	0.9881

Abbreviations: HHM = hand-held myometry; LGMD2B = limb girdle muscular dystrophy type 2B; MFM = Motor Function Measure; MMT = manual muscle testing; SRM = standardized response mean.
This table shows the change scores over 1 year for patients with a diagnosis of LGMD2B or Miyoshi myopathy. Change scores were compared between groups with the Kruskal-Wallis test and Steel-Dwass-Critchlow-Fligner control for multiple comparisons. The SRM is a measure of effect size demonstrated by each test, shown for each diagnostic group. Overall functional scores of the MFM and adapted North Star Ambulatory Assessment did not differ between diagnostic subgroups.
[a] Only 2 muscle groups (ankle plantar flexion and wrist extension) showed a difference between these 2 groups.

Discussion

This analysis supports the use of specified physical and patient-reported outcome measures in the assessment of dysferlinopathy by demonstrating clinically detectable deterioration in muscle strength and function and self-reported deterioration over 6 months and 1 year in a large cohort of patients.

Defining a set of disease specific tests is useful in coordinating further research and patient follow-up and developing clinical trial outcome measures. The most sensitive assessments for monitoring progression in dysferlinopathy that were identified in this study are the a-NSAA, MFM-20, timed 10-meter walk, and Timed Up and Go; they demonstrated consistent change over both 6 months and 1 year with a relatively high SRM. Other tests such as the Brooke and some MMT assessments showed change over 1 year but not 6 months, suggesting that they are less sensitive scales. This was also true for D3 (distal function) of the MFM, consistent with other published cross-sectional data on its poor suitability for this population.[14] Some tests such as the 6MWT and MFM D2 domain changed over one 6-month window but not the other. This poor repeatability of demonstrable change makes these measures less reliable in assessing the dysferlinopathy patient cohort as a whole.

The 6MWT showed the highest SRM for the severely affected ambulant patients, perhaps capturing a large deterioration in the walking pace of some of these weak patients as they lose ambulation. However, this is unlikely to be used in clinical trials, particularly because this subgroup of patients is small (37 severe-ambulant patients in this study), thus reducing the number of patients available to appropriately power a study.

Trials in rare diseases are often forced to rely on small cohort sizes. Here, we show that while variation in physical progression can be high in dysferlinopathy, sensitive outcome measures can be identified (a-NSAA, 10-meter walk, etc.), particularly in ambulant patients. We confirm that a moderate disease severity group based on the a-NSAA could be identified, making it possible to power a clinical trial with a reasonably sized sample. The actual number needed would depend on the expected treatment effect over 1 year. Numbers needed for a trial could be further reduced by using this longitudinal natural history sample as a control group for future clinical studies.[19] In addition, longer evaluation times and identification of more sensitive scoring systems could further reduce the number of participants needed for effective clinical trials. Future work aiming to assess the cohort by modeling methods will look at progression based on a variety of disease and environmental factors to attempt to determine whether any subgroups exist with differing rates of progression. Any particularly fast-progressing group would be very good candidates for potential trials in terms of both patient benefit and reduced sample size requirement.

Increasing the sensitivity and utility of functional scoring systems across the disease spectrum requires the creation of

Table 4 Sample size estimates for a placebo-controlled clinical trial

| | Target treatment effect, n | | | | |
Target study population	50% Reduction in progression	75% Reduction in progression	Halting of progression	20% Improvement	50% Improvement
All ambulant patients	328	148	90	62	42
Moderate patients only (baseline a-NSAA score 11–40)	176	80	46	34	22

Abbreviation: a-NSAA = adapted North Star Ambulatory Assessment.
Sample size estimates for a placebo-controlled clinical trial are based on projected mean change in a-NSAA score for variable treatment effects over 1 year. The numbers represent the total sample size based on equally sized treatment and control groups. Calculations are based on an observed decrease in NSAA score in untreated patients of 2.4 overall and 3.8 among moderate patients, the expected control effect. Estimated change in a-NSAA score among treatment groups over 1 year is therefore as follows: 50% reduction, decrease of 1.2 (all) and 1.9 (moderate) in a-NSAA score; 75% reduction, decrease of 0.6 (all) and 0.9 (moderate) in a-NSAA score; halting of progression, no change in a-NSAA score; 20% improvement, increase of 0.5 (all) and 0.7 (moderate) in a-NSAA score; and 50% improvement, increase of 1.2 (all) and 1.9 (moderate) in a-NSAA score.

a disease-specific scale. We are working to streamline the a-NSAA and MFM-20 to remove redundant and less sensitive items and to combine elements of each scale using a Rasch analysis[20] to create a linearizable, dysferlin-specific score. This modified scale, called the North Star Assessment for Dysferlinopathy, will be validated with the 2- and 3-year COS visits and will be assessed with Rasch analysis to determine whether the new scale is capable of measuring change over a wider proportion of the patient population over time.

Characterizing which individual muscles demonstrate most rapid deterioration in dysferlinopathy is useful for both monitoring progression and targeting potential therapeutics, some of which involve local intramuscular injections.[21] These results over 1 year show some sensitivity to change of a few distal muscle groups in nonambulant patients, in whom functional scores are less useful. However, in ambulant patients, there is a low responsiveness and high variability of MMT and HHD results because measures of specific muscle change. Other measures of strength, longer time scales, and MRI may be needed to monitor effects of local treatments.

In all tests, a small number of individuals of all ages and disease severities improved their time or qualitative functional score over 1 year. While in some this may reflect a true improvement in function, we would not expect an improvement in underlying pathology. Therefore, it is likely that some of this improvement can be attributed to potentially confounding factors. With functional scales, improvement may be due to a learning effect[22]; that is, patients become more practiced at certain tests, although we attempted to mitigate this by having all patients perform a full assessment at screening. Some intertester variation in scoring is also possible because, although all were trained by the same provider, different physiotherapists conducted consecutive patient visits at some sites. However, we anticipate this effect to be small because the functional assessments used have previously demonstrated high intertester reliability in other diseases,[23–25] and intraclass correlation comparison of baseline and screening results (table 5) shows consistency of scoring, particularly for the a-NSAA (intraclass correlation 0.99), on which much of this analysis is based. Finally, this may simply reflect environmental, physiologic, or individual factors such as motivation or fatigue, which can cause natural fluctuations in performance on functional tests[22] on the background of more slowly progressing pathology. If trends in scores are maintained in future visits, suggesting a true subgroup of static or even functionally improving patients, this will be revisited to assess for potential disease modifiers.

Table 5 Intraclass correlation coefficient between screening and baseline assessments for functional tests carried out at a maximum of 90 days apart

Test	Intraclass correlation	n	Multiple
NSAA	0.99	132	119
MFM total score	0.99	170	150
Time to stand	0.85	91	77
Time to walk/run 10 m	0.99	127	114
Timed Up and Go	0.84	112	104
Time to climb 4 steps	0.93	109	101
Time to descend 4 steps	0.53	108	101
6-min walk distance	0.97	129	121
ACTIVLIM	0.97	174	167

Abbreviations: MFM = Motor Function Measure; NSAA = North Star Ambulatory Assessment.
A high intraclass correlation demonstrates consistency between screening and baseline assessments.

The ACTIVLIM is a rating scale with documented high sensitivity in many neuromuscular conditions.[16,26] We have shown that this holds true for the dysferlinopathy population, who show changes in score across all levels of function. A very small number of patients reported an improvement in the ability to perform tasks of daily living. These patients had undertaken lifestyle changes, including weight loss, dietary change, and participation in physiotherapy. Future work will explore and capture patient access to physiotherapy,

participation in exercise, and the use of aids and adaptations in the home and workplace. These findings suggest that the ACTIVLIM is a reliable patient-reported outcome measure in dysferlinopathy that is a valuable complementary tool for clinical trials at any stage of the disease.

There are several limitations of this study. The first is the relatively short period of time over which change was examined; this will be addressed in future analysis of this 3-year study. Second, the use of ordinal, rather than continuous, functional scales presented challenges in data analysis, necessitating the use of medians, making intuitive interpretation more difficult. However, these scales also have benefits because a single point change on a functional change necessarily represents a clinically, rather than simply statistically, noticeable change. Future work will explore the potential to linearize these Rasch-based measures, allowing us to keep the benefits of these scales while providing the opportunity to subject them to more rigorous parametric statistics.

Although function is measured, the importance attributed by patients to the loss of ability to perform 1 particular action over another is not measured here. To clarify the clinical significance of the statistically significant changes demonstrated here, further correlations are needed between these functional and patient-reported measures, as well as consideration of patient valuation of the importance of the loss of individual functions.

Our current assessment of arm function is limited in the scales currently used in this study. Further work is required to develop or determine suitable measures for upper limb function.

This study demonstrates significant population-level change over 6 months and 1 year in several functional and patient-reported measures. We anticipate that the planned combination of the most sensitive elements of the a-NSAA and MFM to create a dysferlin-specific score will produce an important measure that will become the basis for assessment of progression in dysferlinopathy regardless of ambulatory status. This measure combined with MRI data and further patient subgroup analysis will add to the pathophysiologic understanding and trial readiness of the dysferlinopathy population and may further reduce the cohort size required to power potential clinical trials.

Author contributions

Ursula Moore: analysis or interpretation of the data, statistical analysis, drafting or revising the manuscript for intellectual content. Marni Jacobs: statistical analysis. Meredith James, analysis or interpretation of the data, drafting or revising the manuscript for intellectual content. Anna Mayhew and Roberto Fernandez Torron: analysis or interpretation of the data, drafting or revising the manuscript for intellectual content. Jia Feng: analysis or interpretation of the data, statistical analysis.
Avital Cnaan: design or conceptualization of the study, drafting or revising the manuscript for intellectual content. Karen Bettinson: major role in the acquisition of data, drafting or revising the manuscript for intellectual content. Laura Rufibach: design or conceptualization of the study, drafting or revising the manuscript for intellectual content. Robert Muni Lofra, Andrew M. Blamire, and Pierre G. Carlier: design or conceptualization of the study, major role in the acquisition of data, drafting or revising the manuscript for intellectual content. Plavi Mittal: design or conceptualization of the study, drafting or revising the manuscript for intellectual content. Michelle Eagle: design or conceptualization of the study, major role in the acquisition of data, drafting or revising the manuscript for intellectual content. Linda Lowes, Lindsay Alfano, Kristy Rose, Tina Duong, Katherine Berry, Elena Montiel-Morillo, Irene Pedrosa-Hernández, Scott E. Holsten, Mohammed Sanjak, Ai Ashida, Chikako Sakamoto, Tatyuki Tateishi, Hiroyuki Yajima, Aurélie Canal, Gwenn Olliver, Valerie Decostre, Bosco Mendez, Nieves Sánchez-Aguilera Práxedes, Simone Thiele, Catherine Siener, Jeannine Sheierbecker, Julaine Florence, Bruno Vandevelde, Brittney DeWolf, Meghan Harman, Richard Gee, Juliane Prugel, Elke Maron, and Heather Hilsden: major role in the acquisition of data, drafting or revising the manuscript for intellectual content. Hanns Lochmüller: design or conceptualization of the study, drafting or revising the manuscript for intellectual content. Ulrike Grieben, Simone Spuler, Carolina Tesi Rocha, John W. Day, Kristi J. Jones, Diana X. Bharucha-Goebel, Emmanuelle Salort-Campana, Matthew Harms, Alan Pestronk, Sabine Krause, Olivia Schreiber-Katz, Maggie C. Walter, Carmen Paradas, Jean-Yves Hogrel, Tanya Stojkovic, Shin'ich Takeda, Madoka Mori-Yoshimura, Elena Bravver, Susan Sparks, Jordi Díaz-Manera, Luca Bello, Claudio Semplicini, Elena Pegoraro, Jerry R. Mendell, and Kate Bushby: design or conceptualization of the study, major role in the acquisition of data, drafting or revising the manuscript for intellectual content. Volker Straub: design or conceptualization of the study, major role in the acquisition of data, drafting or revising the manuscript for intellectual content, overall responsibility for the content of this paper. For Study Group: the Jain Consortium: All members of the Jain Consortium are listed in the Appendix. All members of the study group played a role in acquisition of data.

Acknowledgment

about the foundation. If you are a patient with dysferlinopathy, please consider enrolling in their interactive dysferlinopathy registry, which seeks to build a strong, engaged, and supportive community (patients@jain-foundation.org).

Study funding

Disclosure

Publication history

Appendix 1 Coinvestigators: The Jain COS Consortium

Coinvestigator	Affiliation and role in study
Adrienne Arrieta, MS	Children's National Medical Center, Washington, DC; data management and training
Esther Hwang	Jain Foundation, Seattle, WA; recruitment, development of assessment form
Elaine Lee, PhD	Jain Foundation, Seattle, WA; recruitment, development of assessment forms
Isabel Illa, MD	Hospital de la Santa Creu i Sant Pau/CIBERER, Barcelona, Spain; site investigator
Eduard Gallardo, MD	Hospital de la Santa Creu i Sant Pau/CIBERER, Barcelona, Spain; site investigator
Izaskun Belmonte Jimeno, PT	Servei de Medicina Física i Rehabilitació, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; site investigator
Jaume Llauger Rossello	Radiology Department, Universitat Autònoma de Barcelona, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; radiologist
Bruce Harwick	Department of Radiology, CMC Mercy Charlotte, Carolinas Healthcare System Neurosciences Institute, Charlotte, NC; NMR technologist
Jackie Sykes, RN, BSN	Carolinas HealthCare System, Charlotte, NC; study coordinator
Brent Yetter, MS	Nationwide Children's Hospital, Columbus, OH; study coordinator
Mark Smith, MS, DABMP, RT (MR)	Department of Radiology, Nationwide Children's Hospital, Columbus, OH; site investigator
Bernard Lapeyssonie, PT	Neuromuscular and ALS Center, La Timone Hospital, Aix-Marseille Université, Marseille, France; site investigator
David Bendahan, PhD	Centre de Résonance, MagnétiqueBiologique et Médicale, UMR CNRS 7339, Marseille, France; Aix-Marseille Université, Marseille, France; site investigator
Yann Le Fur, PhD	Aix-Marseille Université, Marseille, France; site investigator
Attarian Shahram, MD, PhD	Neuromuscular and ALS Center, La Timone Hospital, Aix-Marseille Université, Marseille, France; site investigator
Testot-Ferry Albane, CRA	Neuromuscular and ALS Center, La Timone Hospital, Aix-Marseille Université, Marseille, France; study coordinator
Eva M. Coppenrath, MD	Department of Clinical Radiology, Ludwig-Maximilians-University Munich, Germany; site investigator
Elizabeth Harris, MD	John Walton Muscular Dystrophy Research Centre, Newcastle Upon Tyne, UK; clinical investigator
Michela Guglieri, MD	John Walton Muscular Dystrophy Research Centre, Newcastle Upon Tyne, UK; clinical investigator
Teresinha Evangelista, MD	The John Walton Muscular Dystrophy Research Centre, Newcastle Upon Tyne, UK; clinical investigator
Alex Murphy, MD	The John Walton Muscular Dystrophy Research Centre, Newcastle Upon Tyne, UK; clinical investigator
Dionne Moat	The John Walton Muscular Dystrophy Research Centre, Newcastle Upon Tyne, UK; clinical investigator
Tim Hodgson, MClinRES	Magnetic Resonance Centre, Institute for Cellular Medicine, Newcastle University, Newcastle Upon Tyne, UK; site investigator
Dorothy Wallace, BSc	Magnetic Resonance Centre, Institute for Cellular Medicine, Newcastle University, Newcastle Upon Tyne, UK; site investigator
Louise Ward, DCR	Magnetic Resonance Centre, Institute for Cellular Medicine, Newcastle University, Newcastle Upon Tyne, UK; site investigator
Debra Galley	Magnetic Resonance Centre, Newcastle University, Newcastle Upon Tyne, UK; radiology assistant
Chiara Calore	University of Padova, Padova, Italy, site investigator
Roberto Stramare, MD	Radiology Unit, Department of Medicine, University of Padova, Padova, Italy; site investigator

Continued

Coinvestigator	Affiliation and role in study
Alessandro Rampado, MRT	Radiology Unit, Department of Medicine, University of Padova, Padova, Italy; site investigator
Teresa Gidaro	Institut de Myologie, Paris, France; site investigator
Suna Turk, MSc	AIM & CEA NMR Laboratory, Institute of Myology, Pitié-Salpêtrière University Hospital, 47-83, Paris, France; site investigator
Laurent Servais	Institut de Myologie, Paris, France; site investigator
Cyrille Theis	Institut de Myologie, Paris, France; site investigator
Oumar Diabaté	Institut de Myologie, Paris, France; study coordinator
Linda Schimmoeller	Washington University, St. Louis, MO; study coordinator
Glenn Foster, RTR (MR)	Center for Clinical Imaging Research CCIR, Washington University, St. Louis, MO; site investigator
Pilar Carbonell, MD	Hospital U. Virgen del Rocío/Instituto de Biomedicina de Sevilla, Seville, Spain; site investigator
Macarena Cabrera, MD	Hospital U. Virgen del Rocío/Instituto de Biomedicina de Sevilla, Seville, Spain; site investigator
Yolanda Morgado, MD	Hospital U. Virgen de Valme/Instituto de Biomedicina de Sevilla, Seville, Spain; site investigator
Susana Rico Gala, MD	Department of Radiology, Hospital U. Virgen de Valme, Seville, Spain; site investigator
Jennifer Perez	Stanford University School of Medicine, Stanford, CA; study coordinator
Anne Marie Sawyer, FSMRT	Lucas Centre for Imaging, Stanford University School of Medicine, Stanford, CA; site investigator
Nigel F. Clarke, MD	Institute for Neuroscience and Muscle Research, Sydney, Australia; site investigator
Sarah Sandaradura, MD	Institute for Neuroscience and Muscle Research, Sydney, Australia; site investigator
Roula Ghaoui, MD	Institute for Neuroscience and Muscle Research, Sydney, Australia; site investigator
Kayla Cornett, Ex Phys	Institute for Neuroscience and Muscle Research, Sydney, Australia; site investigator
Claire Miller, PT	Institute for Neuroscience and Muscle Research, Sydney, Australia; site investigator
Sheryl Foster, MHlthSc	Department of Radiology, Westmead Hospital; Faculty of Health Sciences, University of Sydney, Australia; site investigator
Anthony Peduto, MBBS	Department of Radiology, Westmead Hospital; Faculty of Health Sciences, University of Sydney, Australia; site investigator
Noriko Sato, MD, PhD	Department of Radiology, National Center Hospital, National Center of Neurology and Psychiatry, Tokyo, Japan; site investigator
Takeshi Tamaru, MRT	Department of Radiology, National Center Hospital, National Center of Neurology and Psychiatry, Tokyo, Japan; site investigator
Yoko Kobayashi, MD	National Center of Neurology and Psychiatry, Tokyo, Japan; site investigator
Ai Ashida, PT	National Center of Neurology and Psychiatry, Tokyo, Japan; site investigator
Takahiro Nakayama, MD, PhD	Yokohama Rosai Hospital, Yokohama, Japan; study advisor
Kazuhiko Segawa, MD, PhD	National Center of Neurology and Psychiatry, Tokyo, Japan; site investigator
Sachiko Ohtaguro	National Center of Neurology and Psychiatry, Tokyo, Japan; study assistant
Harumasa Nakamura, MD	National Center of Neurology and Psychiatry, Tokyo, Japan; study advisor
Maki Ohhata	National Center of Neurology and Psychiatry, Tokyo, Japan; study coordinator
En Kimura, MD, PhD	National Center of Neurology and Psychiatry, Tokyo, Japan; study advisor
Makiko Endo	National Center of Neurology and Psychiatry, Tokyo, Japan; study coordinator
Nora Brody, PT, DPT	Children's National Health System, Washington, DC: site investigator
Meganne E. Leach, MSN, APRN	Children's National Health System, Washington, DC: site investigator
Allyn Toles	Children's National Health System, Washington, DC: study coordinator
Stanley T. Fricke, PhD	Department of Diagnostic Imaging and Radiology, Children's National Health System, Washington, DC; site investigator
Hansel J. Otero, MD	Department of Diagnostic Imaging and Radiology, Children's National Health System, Washington DC; site investigator

References

1. Bushby K, Straub V. One gene, one or many diseases? Simplifying dysferlinopathy. Neurology 2010;75:298–299.
2. Nguyen K, Bassez G, Bernard R, et al. Dysferlin mutations in LGMD2B, Miyoshi myopathy, and atypical dysferlinopathies. Hum Mutat 2005;26:165.
3. Krahn M, Beroud C, Labelle V, et al. Analysis of the DYSF mutational spectrum in a large cohort of patients. Hum Mutat 2009;30:E345–E375.
4. Harris E, Bladen CL, Mayhew A, et al. The Clinical Outcome Study for Dysferlinopathy: an international multicenter study. Neurol Genet 2016;2:e89.
5. Bushby K, Finkel R, Wong B, et al. Ataluren treatment of patients with nonsense mutation dystrophinopathy. Muscle Nerve 2014;50:477–487.
6. Ryan NJ. Ataluren: first global approval. Drugs 2014;74:1709–1714.
7. Finkel RS, Mercuri E, Darras BT, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med 2017;377(18):1723–32.
8. Mah JK. Current and emerging treatment strategies for Duchenne muscular dystrophy. Neuropsychiatr Dis Treat 2016;12:1795–1807.
9. Shieh PB. Duchenne muscular dystrophy: clinical trials and emerging tribulations. Curr Opin Neurol 2015;28:542–546.
10. Fanin M, Angelini C. Progress and challenges in diagnosis of dysferlinopathy. Muscle Nerve 2016;54:821–835.
11. Klinge L, Aboumousa A, Eagle M, et al. New aspects on patients affected by dysferlin deficient muscular dystrophy. J Neurol Neurosurg Psychiatry 2010;81:946–953.
12. Klinge L, Dean AF, Kress W, et al. Late onset in dysferlinopathy widens the clinical spectrum. Neuromuscul Disord 2008;18:288–290.
13. Angelini C, Peterle E, Gaiani A, Bortolussi L, Borsato C. Dysferlinopathy course and sportive activity: clues for possible treatment. Acta Myol 2011;30:127–132.
14. Woudt L, Di Capua GA, Krahn M, et al. Toward an objective measure of functional disability in dysferlinopathy. Muscle Nerve 2016;53:49–57.
15. Tasca G, Iannaccone E, Monforte M, et al. Muscle MRI in Becker muscular dystrophy. Neuromuscul Disord 2012;22(suppl 2):S100–S106.
16. Batcho CS, Van den Bergh PY, Van Damme P, Roy AJ, Thonnard JL, Penta M. How robust is ACTIVLIM for the follow-up of activity limitations in patients with neuromuscular diseases? Neuromuscul Disord 2016;26:211–220.
17. Husted JA, Cook RJ, Farewell VT, Gladman DD. Methods for assessing responsiveness: a critical review and recommendations. J Clin Epidemiol 2000;53:459–468.
18. Douglas CE, Michael FA. On distribution-free multiple comparisons in the one-way analysis of variance. Commun Stat 1991;20:127–139.
19. Mendell JR, Goemans N, Lowes LP, et al. Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy. Ann Neurol 2016;79:257–271.
20. Mayhew A, Cano S, Scott E, Eagle M, Bushby K, Muntoni F. Moving towards meaningful measurement: Rasch analysis of the North Star Ambulatory Assessment in Duchenne muscular dystrophy. Dev Med Child Neurol 2011;53:535–542.
21. ClinicalTrials.gov. rAAVrh74.MHCK7.DYSF.DV for Treatment of Dysferlinopathies [online]. Available at: clinicaltrials.gov/ct2/show/NCT02710500. Accessed August 24, 2018.
22. Wadsworth CT, Krishnan R, Sear M, Harrold J, Nielsen DH. Intrarater reliability of manual muscle testing and hand-held dynametric muscle testing. Phys Ther 1987;67:1342–1347.
23. Scott E, Eagle M, Mayhew A, et al. Development of a functional assessment scale for ambulatory boys with Duchenne muscular dystrophy. Physiother Res Int 2012;17:101–109.
24. Berard C, Payan C, Hodgkinson I, Fermanian J. A motor function measure for neuromuscular diseases: construction and validation study. Neuromuscul Disord 2005;15:463–470.
25. Cuthbert SC, Goodheart GJ Jr. On the reliability and validity of manual muscle testing: a literature review. Chiropr Osteopat 2007;15:4.
26. Vandervelde L, Van den Bergh PY, Goemans N, Thonnard JL. ACTIVLIM: a Rasch-built measure of activity limitations in children and adults with neuromuscular disorders. Neuromuscul Disord 2007;17:459–469.

Neurology®

This information is current as of January 9, 2019

Updated Information & Services	including high resolution figures, can be found at: http://n.neurology.org/content/92/5/e461.full
References	This article cites 25 articles, 4 of which you can access for free at: http://n.neurology.org/content/92/5/e461.full#ref-list-1
Subspecialty Collections	This article, along with others on similar topics, appears in the following collection(s): **All Neuromuscular Disease** http://n.neurology.org/cgi/collection/all_neuromuscular_disease **Outcome research** http://n.neurology.org/cgi/collection/outcome_research
Permissions & Licensing	Information about reproducing this article in parts (figures,tables) or in its entirety can be found online at: http://www.neurology.org/about/about_the_journal#permissions
Reprints	Information about ordering reprints can be found online: http://n.neurology.org/subscribers/advertise

AMERICAN ACADEMY OF NEUROLOGY®